News Eisai: UK gives pharma a poor deal, may invest elsewhere Japanese pharma getting frustrated with NICE
News NICE rejects Eisai's Halaven in new breast cancer use NICE rejects drug after finding gap in clinical data
News NICE backs funding for Pfizer, Novartis breast cancer drugs Pfizer had been giving drug free to NHS before decision
News NICE to play key role in UK drug fast-track scheme Former GSK CEO Sir Andrew Witty will oversee proceedings.
News Roche's Tecentriq gets three years to prove itself on Cancer... Roche’s Tecentriq has been added to the new-look Cancer Drugs Fund for bladder cancer patients, making it the latest in a recent flurry of drugs to be put on the managed access fund.
News FDA probing cancer cases with Bluebird's CALD gene therapy The FDA is scrutinising reports of haematological cancers in patients treated with bluebird bio's Skysona gene therapy for neurological disease CALD
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
